Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016686267> ?p ?o ?g. }
- W2016686267 endingPage "945" @default.
- W2016686267 startingPage "937" @default.
- W2016686267 abstract "PURPOSE Responses to liver-directed therapy with yttrium 90 microspheres (SIR-Spheres) and adjuvant intraarterial chemotherapy have occurred in patients with unresectable colorectal hepatic metastases who had received less than one chemotherapy regimen. Now, SIR-Spheres are being used to treat patients with advanced disease who have received multiple chemotherapy regimens. A retrospective analysis was performed to determine the technical feasibility of SIR-Sphere treatment in this population. MATERIALS AND METHODS The medical records of 12 patients with hepatic metastatic disease and intrahepatic progression after multiple chemotherapy regimens for unresectable colorectal hepatic metastases who were treated with one or two infusions of SIR-Spheres were retrospectively analyzed for demographics, tumor characteristics, treatment details, response, and survival. RESULTS Twelve patients underwent 17 outpatient infusions of SIR-Spheres. Percent hepatic tumor volume was less than 25% in four patients, 25%–50% in three, and more than 50% in five. Treatment in 11 patients with bilobar disease was accomplished via single infusions in six cases and sequential unilobar infusions in five patients. A single infusion was used to treat unilobar disease in the remaining patient. Median prescribed dose was 39.6 mCi (mean, 37.2 mCi; range, 17–67.5 mCi); the prescribed dose exceeded the delivered dose in six infusions (35%) as a result of embolic arterial occlusion. Radiologic response was stable in five of nine patients. Carcinoembryonic antigen levels decreased in four of seven patients. Four patients received chemotherapy concomitantly or after completion of treatment. Gastric ulceration in one patient was managed nonoperatively. Median survival times from diagnosis and treatment were 24.6 and 4.5 months, respectively. CONCLUSIONS Treatment with SIR-Spheres induces responses in patients with advanced unresectable colorectal hepatic metastases after multiple chemotherapy regimens. Inability to deliver the prescribed dose is related to the embolic effect of SIR-Spheres. Responses to liver-directed therapy with yttrium 90 microspheres (SIR-Spheres) and adjuvant intraarterial chemotherapy have occurred in patients with unresectable colorectal hepatic metastases who had received less than one chemotherapy regimen. Now, SIR-Spheres are being used to treat patients with advanced disease who have received multiple chemotherapy regimens. A retrospective analysis was performed to determine the technical feasibility of SIR-Sphere treatment in this population. The medical records of 12 patients with hepatic metastatic disease and intrahepatic progression after multiple chemotherapy regimens for unresectable colorectal hepatic metastases who were treated with one or two infusions of SIR-Spheres were retrospectively analyzed for demographics, tumor characteristics, treatment details, response, and survival. Twelve patients underwent 17 outpatient infusions of SIR-Spheres. Percent hepatic tumor volume was less than 25% in four patients, 25%–50% in three, and more than 50% in five. Treatment in 11 patients with bilobar disease was accomplished via single infusions in six cases and sequential unilobar infusions in five patients. A single infusion was used to treat unilobar disease in the remaining patient. Median prescribed dose was 39.6 mCi (mean, 37.2 mCi; range, 17–67.5 mCi); the prescribed dose exceeded the delivered dose in six infusions (35%) as a result of embolic arterial occlusion. Radiologic response was stable in five of nine patients. Carcinoembryonic antigen levels decreased in four of seven patients. Four patients received chemotherapy concomitantly or after completion of treatment. Gastric ulceration in one patient was managed nonoperatively. Median survival times from diagnosis and treatment were 24.6 and 4.5 months, respectively. Treatment with SIR-Spheres induces responses in patients with advanced unresectable colorectal hepatic metastases after multiple chemotherapy regimens. Inability to deliver the prescribed dose is related to the embolic effect of SIR-Spheres." @default.
- W2016686267 created "2016-06-24" @default.
- W2016686267 creator A5002087124 @default.
- W2016686267 creator A5002650017 @default.
- W2016686267 creator A5009068086 @default.
- W2016686267 creator A5019320471 @default.
- W2016686267 creator A5020745931 @default.
- W2016686267 creator A5022732881 @default.
- W2016686267 creator A5030665581 @default.
- W2016686267 creator A5034845901 @default.
- W2016686267 creator A5040833374 @default.
- W2016686267 creator A5072198648 @default.
- W2016686267 creator A5078108582 @default.
- W2016686267 date "2005-07-01" @default.
- W2016686267 modified "2023-09-28" @default.
- W2016686267 title "Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results" @default.
- W2016686267 cites W1966703018 @default.
- W2016686267 cites W1974613296 @default.
- W2016686267 cites W1975777455 @default.
- W2016686267 cites W1986421985 @default.
- W2016686267 cites W2004557616 @default.
- W2016686267 cites W2010047598 @default.
- W2016686267 cites W2010397777 @default.
- W2016686267 cites W2020631261 @default.
- W2016686267 cites W2023203105 @default.
- W2016686267 cites W2052702202 @default.
- W2016686267 cites W2062684877 @default.
- W2016686267 cites W2076668534 @default.
- W2016686267 cites W2085821047 @default.
- W2016686267 cites W2086409122 @default.
- W2016686267 cites W2088591216 @default.
- W2016686267 cites W2093941737 @default.
- W2016686267 cites W2109819743 @default.
- W2016686267 cites W2120579772 @default.
- W2016686267 cites W2131740088 @default.
- W2016686267 cites W2135423900 @default.
- W2016686267 cites W2136885732 @default.
- W2016686267 cites W2156946556 @default.
- W2016686267 cites W2157769714 @default.
- W2016686267 cites W2164145964 @default.
- W2016686267 cites W2280121169 @default.
- W2016686267 cites W4294113097 @default.
- W2016686267 doi "https://doi.org/10.1097/01.rvi.0000161142.12822.66" @default.
- W2016686267 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16002501" @default.
- W2016686267 hasPublicationYear "2005" @default.
- W2016686267 type Work @default.
- W2016686267 sameAs 2016686267 @default.
- W2016686267 citedByCount "139" @default.
- W2016686267 countsByYear W20166862672012 @default.
- W2016686267 countsByYear W20166862672013 @default.
- W2016686267 countsByYear W20166862672014 @default.
- W2016686267 countsByYear W20166862672015 @default.
- W2016686267 countsByYear W20166862672016 @default.
- W2016686267 countsByYear W20166862672017 @default.
- W2016686267 countsByYear W20166862672018 @default.
- W2016686267 countsByYear W20166862672019 @default.
- W2016686267 countsByYear W20166862672020 @default.
- W2016686267 countsByYear W20166862672021 @default.
- W2016686267 countsByYear W20166862672023 @default.
- W2016686267 crossrefType "journal-article" @default.
- W2016686267 hasAuthorship W2016686267A5002087124 @default.
- W2016686267 hasAuthorship W2016686267A5002650017 @default.
- W2016686267 hasAuthorship W2016686267A5009068086 @default.
- W2016686267 hasAuthorship W2016686267A5019320471 @default.
- W2016686267 hasAuthorship W2016686267A5020745931 @default.
- W2016686267 hasAuthorship W2016686267A5022732881 @default.
- W2016686267 hasAuthorship W2016686267A5030665581 @default.
- W2016686267 hasAuthorship W2016686267A5034845901 @default.
- W2016686267 hasAuthorship W2016686267A5040833374 @default.
- W2016686267 hasAuthorship W2016686267A5072198648 @default.
- W2016686267 hasAuthorship W2016686267A5078108582 @default.
- W2016686267 hasConcept C121608353 @default.
- W2016686267 hasConcept C126322002 @default.
- W2016686267 hasConcept C141071460 @default.
- W2016686267 hasConcept C167135981 @default.
- W2016686267 hasConcept C2776694085 @default.
- W2016686267 hasConcept C2777387746 @default.
- W2016686267 hasConcept C2781413609 @default.
- W2016686267 hasConcept C71924100 @default.
- W2016686267 hasConcept C90924648 @default.
- W2016686267 hasConceptScore W2016686267C121608353 @default.
- W2016686267 hasConceptScore W2016686267C126322002 @default.
- W2016686267 hasConceptScore W2016686267C141071460 @default.
- W2016686267 hasConceptScore W2016686267C167135981 @default.
- W2016686267 hasConceptScore W2016686267C2776694085 @default.
- W2016686267 hasConceptScore W2016686267C2777387746 @default.
- W2016686267 hasConceptScore W2016686267C2781413609 @default.
- W2016686267 hasConceptScore W2016686267C71924100 @default.
- W2016686267 hasConceptScore W2016686267C90924648 @default.
- W2016686267 hasIssue "7" @default.
- W2016686267 hasLocation W20166862671 @default.
- W2016686267 hasLocation W20166862672 @default.
- W2016686267 hasOpenAccess W2016686267 @default.
- W2016686267 hasPrimaryLocation W20166862671 @default.
- W2016686267 hasRelatedWork W1586374228 @default.
- W2016686267 hasRelatedWork W2003938723 @default.
- W2016686267 hasRelatedWork W2047967234 @default.
- W2016686267 hasRelatedWork W2089201504 @default.